Supporting the lifestyle modification and treatment of type 2 diabetes for people with severe mental illness

European Diabetes Nursing

Volumn 5, Issue 2, 2008, Pages 58-63

  Pendlebury, John ^a   Holt, R I G ^b  

^a University of Southampton ^*  (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Antipsychotic; Diabetes; Schizophrenia; Severe mental illness

Indexed keywords

EID: 55349098262     PISSN: 15517853     EISSN: 15517861     Source Type: Journal    
DOI: 10.1002/edn.110     Document Type: Review

References (30)

1. Maudsley H. The Pathology of Mind, 3rd edn. London: Macmillan, 1879.
2. Holt RI, Bushe C, Citrome L. Diabetes and schizophrenia 2005: are we any closer to understanding the link? J Psychopharmacol 2005; 19: 56-65.
3. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psych Clin Neurosci 2000; 250: 274-285.
4. Citrome L. Metabolic syndrome and cardiovascular disease. J Psychopharmacol 2005; 19: 84-93.
5. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19-32.
6. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212-217.
7. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29: 697-701.
8. McCreadie R, Macdonald E, Blacklock C, et al. Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study. Br Med J 1998; 317: 784-785.
9. Gough SC, O'Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol 2005; 19: 47-55.
10. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160: 284-289.
11. Thakore JH, Mann JN, Vlahos I, et al. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Rel Metab Disord 2002; 26: 137-141.
12. Dinan TG. Stress and the genesis of diabetes mellitus in schizophrenia. Br J Psychiatry Suppl 2004; 47: 72-75.
13. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 1968; 124: 978-982.
14. Hiles BW. Hyperglycaemia and glucosuria following chlorpromazine therapy. JAMA 1956; 162: 1651.
15. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002; 14: 59-64.
16. Holt RI, Peveler RC. Antipsychotic drugs and diabetes - an application of the Austin Bradford Hill criteria. Diabetologia 2006; 49: 1467-1476.
17. Citrome LL, Holt RI, Zachry WM, et al. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother 2007; 41: 1593-1603.
18. Holt RI, Peveler RC. Association between antipsychotic drugs and diabetes. Diabetes Obes Metab 2006; 8: 125-135.
19. Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003; 48: 345-347.
20. Voruganti LP, Punthakee Z, Van Lieshout RJ, et al. Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DISCO) study. Schizophr Res 2007; 96: 215-222.
21. Citrome L, Yeomans D. Do guidelines for severe mental illness promote physical health and well-being? J Psychopharmacol 2005; 19: 102-109.
22. National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical guidelines 1. London: NICE, 2002 (http://www.nice.org.uk).
23. 'Schizophrenia and Diabetes 2003' Expert Consensus Meeting, Dublin, 3-4 October 2003: consensus summary. Br J Psychiatry Suppl 2004; 47: 112-114.
24. Taylor D, Young C, Esop R, et al. Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 2004; 185: 152-156.
25. Holt RIG, Peveler RC. The high prevalence of undiagnosed metabolic complications in people with severe mental illness. Diabetic Med 2007; 24(Suppl 1): P251
26. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
27. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-544.
28. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med 2002; 346: 393-403.
29. Diabetes Prevention Program Research Group. Long-term maintenance of weight loss in patients with severe mental illness through a behavioral treatment programme in the UK. Acta Psychiatr Scand 2007; 115: 286-294.
30. Menza M, Vreeland B, Minsky S, et al. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 2004; 65: 471-477.